16 To 24 Amino Acid Residues In The Peptide Chain Patents (Class 514/21.4)
  • Patent number: 11135163
    Abstract: Peptide hydrogels having a self-assembling, 3-dimensional nanofiber matrix are described. The nanofiber matrix comprises an amphiphilic peptide and optionally albumin. The peptide comprises (consists of) a terminal hydrophobic region, a central turning region, and a terminal hydrophilic region. Methods of making such hydrogels are also described, along with methods of using the hydrogels as scaffolding for tissue engineering, hemostatic agents, as well as 3-dimensional cell cultures, and for drug delivery, encapsulation of active agents (therapeutic cells, molecules, drugs, compounds), cell transplantation, cell storage, virus culture and storage.
    Type: Grant
    Filed: August 22, 2018
    Date of Patent: October 5, 2021
    Assignee: Kansas State University Research Foundation
    Inventors: Xiuzhi S. Sun, Hongzhou Huang, Tiffany L. Carter, Mark L. Weiss
  • Patent number: 11077163
    Abstract: A pharmaceutical composition for preventing or treating ophthalmopathy is described. More particularly, a composition comprising a peptide derived from telomerase and being effective in treating and preventing ophthalmopathy is described. The peptide derived from telomerase, a peptide having a sequence 80% identical to the sequence thereof, or a peptide as a fragment thereof is superiorly effective in treating ophthalmopathy.
    Type: Grant
    Filed: September 25, 2019
    Date of Patent: August 3, 2021
    Assignee: GemVax & KAEL Co., Ltd.
    Inventor: Sang Jae Kim
  • Patent number: 11033604
    Abstract: Disclosed herein are ?-sheet peptides and their use for treating a bacterial infection and/or limiting bacterial biofilm formation.
    Type: Grant
    Filed: January 25, 2019
    Date of Patent: June 15, 2021
    Assignee: University of Washington
    Inventors: Valerie Daggett, Alissa Bleem
  • Patent number: 10906939
    Abstract: Provided herein are charge complementary peptides that can be optionally coupled to a cargo polypeptide that are capable of self-assembling under stimulating conditions. The charge complementary peptides can be capable of forming supramolecular structures. Also provided herein are methods of using the charge complementary peptides provided herein.
    Type: Grant
    Filed: August 9, 2017
    Date of Patent: February 2, 2021
    Assignee: University of Florida Research Foundation, Incorporated
    Inventors: Gregory Allan Hudalla, Dillon T. Seroski
  • Patent number: 10865394
    Abstract: The present disclosure provides a system to produce soluble, folded, and post-translationally modified proteins. The system includes a fusion protein comprising a catalytic domain of an enzyme involved in post-translational protein modification and a targeting domain, and a substrate protein comprising a protein of interest and a sequence that interacts with the targeting domain. The present disclosure also provides polynucleotide sequences encoding fusion proteins and substrate proteins, vectors for expressing polynucleotide sequences, vectors comprising the polynucleotide sequences, and isolated cells comprising said vectors.
    Type: Grant
    Filed: September 20, 2017
    Date of Patent: December 15, 2020
    Assignee: Washington University
    Inventors: Kristen Naegle, Roman Sloutsky
  • Patent number: 10772929
    Abstract: Method of use of peptides and their analogs in the treatment of acute pancreatitis are described. The disclosed peptides and analogs can significantly lower the elevated blood amylase and lipase levels caused by acute pancreatitis, reduce the degree of injury observed in pancreatic histopathology caused by pancreatitis, and significantly lower the mortality rate of acute pancreatitis.
    Type: Grant
    Filed: May 11, 2017
    Date of Patent: September 15, 2020
    Assignee: SHENZHEN HIGHTIDE BIOPHARMACEUTICAL, LTD.
    Inventors: Liping Liu, Ru Bai
  • Patent number: 10519212
    Abstract: Disclosed in the present invention is a long-acting recombinant human follicle-stimulating hormone-Fc fusion protein (referred to as hFSH-Fc for short) and a preparation method thereof, wherein the hFSH-Fc protein is a dimerized fusion protein and the amino acid sequence thereof successively comprises an hFSH? subunit, CTP, an hFSH? subunit, a flexible peptide linker and human IgG2 Fc variant from N-terminal to C-terminal. Also disclosed in the present invention is the use of the recombinant hFSH-Fc fusion protein composition in preparing drugs in the animal breeding field.
    Type: Grant
    Filed: August 22, 2014
    Date of Patent: December 31, 2019
    Assignee: GUANGZHOU VBIO PHARMA CO., LTD.
    Inventors: Yongmin Hou, Yao Lei, Henglu Deng
  • Patent number: 10449269
    Abstract: Composite prosthetic patches with covalently bound particles for controlled drug release, and methods of making and using thereof, have been developed. The particles may encapsulate one or more therapeutic, prophylactic or diagnostic agent(s). Generally, the prosthetic patches are decellularized extracellular matrix such as bovine or porcine pericardium or synthetic polymeric materials. The size of the particles ranges from between 1 nm and 1000 ?m, preferably from between 10 nm and 500 nm. In some embodiments, the agent is a therapeutic agent for treatment of neointimal hyperplasia. In other embodiments, the agent is a therapeutic agent for suppressing or resolving inflammation. In yet other embodiments, the agent is a therapeutic for mitigating scarring.
    Type: Grant
    Filed: August 28, 2017
    Date of Patent: October 22, 2019
    Assignee: YALE UNIVERSITY
    Inventors: Tarek M. Fahmy, Alan Dardik
  • Patent number: 10245299
    Abstract: Materials and methods for treatment of pulmonary bulla are provided. A peptide comprising between about 7 amino acids and about 32 amino acids in a solution may be introduced to a target site. A hydrogel barrier may be provided at the target site in order to treat the pulmonary bulla.
    Type: Grant
    Filed: March 10, 2015
    Date of Patent: April 2, 2019
    Assignee: 3-D Matrix, Ltd.
    Inventors: Manav Mehta, Hisashi Tsukada, Eun Seok Gil, Karl Gilbert, Satoru Kobayashi
  • Patent number: 10227390
    Abstract: Provided herein are stabilized ?-CT polypeptides comprising an alpha-helical segment, and wherein the polypeptide is of Formula (I-1) or Formula (I-2): Rf—[XAA]s—XA1—XA2—XA3—XA4—XA5—XA6—XA7—XA8—XA9—XA10—XA11—XA12—XA13—XA14—[XAA]t—Re (I-1) Rf—[XAA]s—XC1—XC2—XC3—XC4—XC5—XC6—XC7—XC8—XC9—XC10—XC11—XC12—XC13—XC14—XC15—XC16—XC17—XC18—XC19—XC20—[XAA]t—Re (I-2) wherein the ?-CT polypeptide binds to the insulin receptor, and wherein the ?-CT polypeptide includes at least one staple (i.e. two cross-linked amino acids) and/or at least one stitch (i.e. three cross-linked amino acids). Further provided are insulin analogs including the stapled or stitched ?-CT polypeptides, pharmaceutical compositions thereof, methods of use, e.g., methods of treating a diabetic condition or complications thereof.
    Type: Grant
    Filed: June 13, 2014
    Date of Patent: March 12, 2019
    Assignee: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Gregory L. Verdine, Gerard Hilinski, Rebecca Yue Liang, Yvonne Alice Nagel, Minyun Zhou
  • Patent number: 10227383
    Abstract: This invention relates to an IgG-binding peptide, an IgG-binding peptide modified with a cross-linking agent, a conjugate of the IgG-binding peptide modified with a cross-linking agent and IgG, and a method for producing the conjugate, etc.
    Type: Grant
    Filed: May 20, 2016
    Date of Patent: March 12, 2019
    Assignee: Kagoshima University
    Inventor: Yuji Ito
  • Patent number: 10196424
    Abstract: Peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel disease, are disclosed.
    Type: Grant
    Filed: February 24, 2017
    Date of Patent: February 5, 2019
    Assignee: Protagonist Therapeutics, Inc.
    Inventors: Gregory Bourne, Ashok Bhandari, Xiaoli Cheng, Brian Troy Frederick, Jie Zhang, Dinesh V. Patel, David Liu
  • Patent number: 10155022
    Abstract: The disclosure relates to a fat accumulation inhibitory peptide which essentially comprises an amino acid sequence represented by SEQ ID NO: 1, a pharmaceutical composition for preventing or treating obesity, which contains the peptide, and a health functional food for preventing or alleviating obesity, which contains the peptide. The fat accumulation inhibitory peptide according to the present invention has the function of inhibiting the differentiation of mesenchymal stem cells into adipocytes to thereby inhibit the accumulation of adipose tissue. Thus, the peptide according to the present invention is highly useful for the prevention or treatment of obesity.
    Type: Grant
    Filed: August 1, 2017
    Date of Patent: December 18, 2018
    Assignees: SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION, NANO INTELLIGENT BIOMEDICAL ENGINEERING CORPORATION CO. LTD.
    Inventors: Chong-Pyoung Chung, Yoon Jeong Park, Jue-Yeon Lee, Jin Sook Suh, In Ho Jo, Yoon Shin Park
  • Patent number: 10034922
    Abstract: A peptide having angiogenesis inhibition activity and pharmaceutical composition comprising thereof is described. More specifically, the application relates to the pharmaceutical composition for inhibiting angiogenesis comprising the peptide as a peptide derived from telomerase.
    Type: Grant
    Filed: November 21, 2014
    Date of Patent: July 31, 2018
    Assignee: GemVax & KAEL Co., Ltd.
    Inventor: Sang Jae Kim
  • Patent number: 10030059
    Abstract: Peptide antagonists of ?c-family cytokines, which is associated with important human diseases, such as leukemia, autoimmune diseases, collagen diseases, diabetes mellitus, skin diseases, degenerative neuronal diseases and graft-versus-host disease (GvHD). Thus, inhibitors of ?c-cytokine activity are valuable therapeutic and cosmetic agents as well as research tools. Traditional approaches to inhibiting ?c-cytokine activity involve raising neutralizing antibodies against each individual ?c-cytokine family member/receptor subunit. However, success has been limited and often multiple ?c-cytokine family members co-operate to cause the disease state. Combinatorial use of neutralizing antibodies raised against each factor is impractical and poses an increased risk of adverse immune reactions. The present embodiments overcome these shortcomings by utilizing peptide antagonists based on the consensus ?c-subunit binding site to inhibit ?c-cytokine activity. Such approach allows for flexibility in antagonist design.
    Type: Grant
    Filed: May 3, 2017
    Date of Patent: July 24, 2018
    Assignee: BIONIZ, LLC
    Inventor: Nazli Azimi
  • Patent number: 9963483
    Abstract: An object of the present invention is to provide a process capable of producing a self-assembling peptide derivative that is useful in the fields of regenerative medicine and surgery in large quantities and in an economical and efficient manner. In particular, provided is a production process employing a combination of (i) a step of convergently constructing a sequence with use of a common repeating unit consisting of a specific amino acid sequence and (ii) a step of first isolating the peptide derivative as a disulfuric acid salt, a tetramethanesulfonic acid salt or a tetra(trifluoroacetic acid (TFA) salt), and then subjecting the peptide salt to a salt exchange reaction to yield a tetrahydrochloric acid salt.
    Type: Grant
    Filed: July 12, 2013
    Date of Patent: May 8, 2018
    Assignee: MENICON CO., LTD.
    Inventors: Hidenori Yokoi, Yasuhiro Yokoyama, Keisuke Matsuyama, Kenichiro Yamamoto, Kinsei Anzai, Daisuke Nakamura, Toyohiro Nagano, Kazuya Kodama
  • Patent number: 9962465
    Abstract: A method to regrow a protective layer over exposed/demineralized dentin that includes a step of identifying a subject having exposed/demineralized dentin. The demineralized dentin is contacted with a remineralization composition that includes an amelogenin and derived peptides, a chitosan, water, and a sufficient amount of a pH adjusting component such that the composition has a pH greater than about 6.0 such that dentinal tubules are occluded with apatite crystals and enamel is regrown on the dentinal tubules.
    Type: Grant
    Filed: July 6, 2016
    Date of Patent: May 8, 2018
    Assignee: University of Southern California
    Inventors: Janet Moradian-Oldak, Qichao Ruan, Kaushik Mukherjee
  • Patent number: 9617305
    Abstract: The present invention provides pharmaceutical compositions and methods of treating lower gastrointestinal disorders, including inflammatory bowel disease (IBD), diverticulitis, colon cancer, an inflammatory disorder, obesity, congestive heart failure, benign prostatic hyperplasia (BPH), pain, salt retention or fluid retention.
    Type: Grant
    Filed: June 8, 2012
    Date of Patent: April 11, 2017
    Assignee: Ironwood Pharmaceuticals, Inc.
    Inventors: Mark G. Currie, Daniel P. Zimmer, Angelika Fretzen, Marco Kessler, Brian M. Cali
  • Patent number: 9604919
    Abstract: Provided are crystalline ?, ?-disubstituted amino acids and their crystalline salts containing a terminal alkene on one of their side chains, as well as optionally crystalline halogenated and deuterated analogs of the ?, ?-disubstituted amino acids and their salts; methods of making these, and methods of using these.
    Type: Grant
    Filed: November 1, 2013
    Date of Patent: March 28, 2017
    Assignee: AILERON THERAPEUTICS, INC.
    Inventors: Krzysztof Darlak, Noriyuki Kawahata, Sameer Ahmed Athamneh
  • Patent number: 9527887
    Abstract: The present invention provides pharmaceutical compositions and methods of treating lower gastrointestinal disorders, including irritable bowel syndrome and constipation.
    Type: Grant
    Filed: June 8, 2012
    Date of Patent: December 27, 2016
    Assignee: Ironwood Pharmaceutical, Inc.
    Inventors: Mark G. Currie, Daniel P. Zimmer, Angelika Fretzen, Marco Kessler, Brian M. Cali
  • Patent number: 9415084
    Abstract: Self assembling peptides and peptidomimetics can be utilized for the treatment and support of disorders associated with leaky or damaged tight junction and weak, diseased, or injured extracellular matrix. The self-assembling materials generally have alternating hydrophilic or hydrophobic residues or hydrophobic and/or hydrophilic sections which allow the material to react or interact with the glycoproteins found in the ECM. Diseases in which treatment with these materials applied to or near the site in need of treatment include diabetic retinopathy, sepsis, burns, and certain neurodegenerative diseases such as Parkinson's and Alzheimer's. The formulations can be administered by injection, spraying, topically or by catheter or via a wound dressing or other material to which it is applied and then applied to the site in need of treatment.
    Type: Grant
    Filed: March 14, 2008
    Date of Patent: August 16, 2016
    Assignee: Arch Biosurgery, Inc.
    Inventors: Rutledge Ellis-Behnke, Terrence W. Norchi, Stephen Richard Kelly
  • Patent number: 9403884
    Abstract: A peptide having an amino acid sequence containing at least eight consecutive amino acids of the human lactoferrin protein or of the bovine lactoferrin protein. The peptide is suitable as a cell-penetrating peptide. A complex of the peptide and a cargo molecule non-covalently bound to the peptide. The cargo molecule may be a nucleic acid, an amino acid, a peptide, a protein, a carbohydrate, a lipid, or a small molecule. A method of penetrating or transfecting a cell using the complex.
    Type: Grant
    Filed: July 25, 2012
    Date of Patent: August 2, 2016
    Assignee: Evonik Roehm GmbH
    Inventors: Roland Brock, Rainer Fischer, Mariola Fotin-Mleczek, Hansjoerg Hufnagel, Norbert Windhab
  • Patent number: 9233149
    Abstract: This invention provides WT1 peptides and methods of treating, reducing the incidence of, and inducing immune responses against a WT1-expressing cancer, comprising same.
    Type: Grant
    Filed: September 16, 2013
    Date of Patent: January 12, 2016
    Assignee: SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH
    Inventors: David A. Scheinberg, Javier Pinilla-Ibarz, Rena May
  • Patent number: 9221875
    Abstract: Disclosed is the method of treating keratits in a subject thereof comprising administering into the subject an amphiphilic peptides of the present disclosure. Also disclosed are methods of removing biofilm from cornea.
    Type: Grant
    Filed: July 1, 2014
    Date of Patent: December 29, 2015
    Assignee: Agency for Science, Technology and Research
    Inventors: Yi-Yan Yang, Zhan Yuin Ong
  • Patent number: 9192569
    Abstract: A liquid colloidal pharmaceutical formulation of a type B lantibiotic for infusion or direct injection is described, the formulation being clear of visual particulates and comprising a type B lantibiotic or a salt thereof, an isotonic aqueous solution comprising a sugar alcohol and optionally a buffer.
    Type: Grant
    Filed: August 9, 2011
    Date of Patent: November 24, 2015
    Assignee: Novacta Biosystems Limited
    Inventors: Antony Nicholas Appleyard, Sjoerd Nicolaas Wadman
  • Patent number: 9139636
    Abstract: Compositions of purified biologically active Wnt proteins are provided. Wnt proteins are found to be hydrophobic and post-translationally modified by addition of a lipid moiety at a conserved cysteine residue. Methods for isolation of Wnt utilize detergents that maintain the solubility of the modified protein.
    Type: Grant
    Filed: January 16, 2014
    Date of Patent: September 22, 2015
    Assignee: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
    Inventors: Roeland Nusse, Karl H. Willert
  • Patent number: 9097717
    Abstract: The present invention provides a therapeutic agent, for diseases in which neoplastic proliferation of plasma cells occurs, which is characterized by containing an anti-human CD48 monoclonal antibody and having cellular cytotoxicity to cells expressing human CD48; and the monoclonal antibody. In addition, the present invention provides a method for screening an active ingredient of a therapeutic agent for diseases in which neoplastic proliferation of plasma cells occurs, the method including the following processes: (1) a process of sorting a substance that binds specifically to human CD48; and (2) a process of sorting a substance having cellular cytotoxicity.
    Type: Grant
    Filed: April 9, 2010
    Date of Patent: August 4, 2015
    Assignee: OSAKA UNIVERSITY
    Inventors: Naoki Hosen, Haruo Sugiyama
  • Publication number: 20150148302
    Abstract: The present invention relates to compositions, including membrane permeable complexes, comprising a Caspase 2 activation inhibitory peptide having the amino acid sequence AFDAFC as well as methods of using the same for the treatment of neurodegenerative conditions associated with apoptosis in the central nervous system, such as Alzheimer's Disease, Mild Cognitive Impairment, Parkinson's Disease, amyotrophic lateral sclerosis, Huntington's chorea, and Creutzfeld-Jacob disease.
    Type: Application
    Filed: March 7, 2014
    Publication date: May 28, 2015
    Applicant: The Trustees of Columbia University in the city of New York
    Inventor: Carol M. Troy
  • Patent number: 9040662
    Abstract: In an aspect, the invention relates to compositions and methods for permeabilizing membranes of cells. In an aspect, the invention relates to compositions and methods for killing cells. In an aspect, the invention relates to compositions and methods of permeabilizing the membranes of cancer cells or microbial cells.
    Type: Grant
    Filed: August 24, 2012
    Date of Patent: May 26, 2015
    Assignee: UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION
    Inventors: Annette Khaled, Rebecca Boohaker, Michael Lee, Jesus Perez Figueroa
  • Publication number: 20150139955
    Abstract: A peptide dimer comprising a peptide consisting of the amino acid sequence of SEQ ID NO: 1 and a peptide consisting of any one of the amino acid sequences of SEQ ID NOS: 2 to 4, wherein the peptide consisting of the amino acid sequence of SEQ ID NO: 1 and the peptide consisting of any one of the amino acid sequences of SEQ ID NOS: 2 to 4 are bound through a disulfide bond between a cysteine residue of each peptide is used as an active ingredient of an agent for promoting proliferation of one or more bacterium selected from the group consisting of Bifidobacterium infantis and Bifidobacterium breve.
    Type: Application
    Filed: August 24, 2012
    Publication date: May 21, 2015
    Applicant: MORINAGA MILK INDUSTRY CO., LTD.
    Inventors: Hirotsugu Oda, Koji Yamauchi, Takumi Sato, Kanetada Shimizu
  • Publication number: 20150140060
    Abstract: Provided herein are compositions and methods for use in promoting wound healing and tissue regeneration following tissue injury in a subject.
    Type: Application
    Filed: November 14, 2014
    Publication date: May 21, 2015
    Inventor: Gautam GHATNEKAR
  • Publication number: 20150139907
    Abstract: This invention provides novel methods for inducing hair growth and/or inhibiting hair loss and/or inducing nail growth in a mammal. In various embodiments the methods involve administering, e.g., to a mammal in need thereof, a calcium-binding peptide and/or peptide-like moiety in an amount sufficient to induce hair growth and/or to inhibit hair loss. In certain embodiments the agent is topically and/or transdermally administered.
    Type: Application
    Filed: October 14, 2014
    Publication date: May 21, 2015
    Inventors: Daniel K. Yarbrough, Xiaoyang Wu, Wenyuan Shi, Maxwell H. Anderson
  • Publication number: 20150141350
    Abstract: A nanodevice composition including N-acetyl cysteine linked to a dendrimer, such as a PAMAM dendrimer or a multiarm PEG polymer, is provided. Also provided is a nanodevice for targeted delivery of a compound to a location in need of treatment. The nanodevice includes a PAMAM dendrimer or multiarm PEG polymer, linked to the compound via a disulfide bond. There is provided a nanodevice composition for localizing and delivering therapeutically active agents, the nanodevice includes a PAMAM dendrimer or multiarm PEG polymer and at least one therapeutically active agent attached to the PAMAM dendrimer or multiarm PEG polymer.
    Type: Application
    Filed: September 4, 2014
    Publication date: May 21, 2015
    Inventors: Rangaramanujam M. Kannan, Sujatha Kannan, Roberto Romero, Raghavendra S. Navath, Hui Dai, Anupa R. Menjoge
  • Patent number: 9034825
    Abstract: Provided are methods of using humanin and humanin analogs to treat a mammal exhibiting or at risk for insulin resistance, increase insulin sensitivity in a mammal exhibiting or at risk for insulin resistance, treat type-2 diabetes mellitus, metabolic syndrome, and neurodegeneration, treat and prevent myocardial injury, and determine longevity.
    Type: Grant
    Filed: February 21, 2014
    Date of Patent: May 19, 2015
    Assignee: Albert Einstein College of Medicine of Yeshiva University
    Inventors: Radhika Muzumdar, David J. Lefer
  • Publication number: 20150133385
    Abstract: Peptide compounds derived from human melanotransferrin, and compositions thereof, are described. Uses of these peptide compounds, for example to modulate angiogenesis and/or cell migration, and/or to treat angiogenesis-related disorders (e.g., cancer), are also described.
    Type: Application
    Filed: October 18, 2012
    Publication date: May 14, 2015
    Inventors: Richard Béliveau, Jonathan Michaud-Levesque, Krishna G. Peri, Abdelkrim Habi, Nathalie Bousquet-Gagnon
  • Publication number: 20150126451
    Abstract: The present invention relates generally to tissue differentiation factor (TDF) analogs. More specifically, the invention relates to structure-based methods and compositions useful in designing, identifying, and producing molecules, which act as functional modulators of TDF-like receptors. The invention further relates to methods of detecting, preventing, and treating TDF-associated disorders.
    Type: Application
    Filed: November 5, 2014
    Publication date: May 7, 2015
    Inventors: William D. Carlson, Peter C. Keck, Michael Sworin, Dattatreyamurty Bosukonda, Kellie Watson, Philippe Bey, Romesh Subramanian
  • Publication number: 20150126460
    Abstract: The invention provides methods of delivering pharmacologic agents linked to an internalization peptide, in which an inflammatory response inducible by the internalization peptide is inhibited by co-administration of an anti-inflammatory or by linking the internalization peptide to biotin or similar molecule. Such methods are premised in part on the results described in the examples whereby administration of a pharmacological agent linked to tat at high dosages is closely followed by an inflammatory response, which includes mast cell degranulation, histamine release and the typical sequelae of histamine release, such as redness, heat, swelling, and hypotension.
    Type: Application
    Filed: December 29, 2014
    Publication date: May 7, 2015
    Applicant: NoNO Inc.
    Inventors: Michael Tymianski, Jonathan David Garman, Hong Cui
  • Publication number: 20150126450
    Abstract: Novel peptoid oligomers are disclosed that have a formula represented by the following formula Ia or Ib: The peptoid oligomers are prepared as modulators of androgen receptor (AR), and may be prepared as pharmaceutical compositions and used for the prevention or treatment of a variety of conditions in mammals, including humans, associated with unwanted or aberrant AR activity. The present peptoid oligomers are particularly valuable for the treatment of subjects with cancer.
    Type: Application
    Filed: April 16, 2013
    Publication date: May 7, 2015
    Inventors: Kent Kirshenbaum, Paul Michael Levine, Michael John Garabedian
  • Patent number: 9023806
    Abstract: The invention concerns a peptide derived from intermediate filaments and an intermediate filament fragment capable of altering tubulin polymerization and used for inhibiting cell proliferation, and more particularly for obtaining medicines designed to prevent or treat diseases involving cell proliferation, such as cancers for example.
    Type: Grant
    Filed: April 21, 2005
    Date of Patent: May 5, 2015
    Assignees: Universite d'Angers, Institut National de la Sante et de la Recherche Medicale (Inserm), McGill University
    Inventors: Arnaud Bocquet, Joël Eyer, Alan Peterson
  • Publication number: 20150118315
    Abstract: A finished pharmaceutical product adapted for oral delivery of an aromatic-cationic peptide, wherein the product comprises a therapeutically effective amount of the peptide; at least one pharmaceutically acceptable pH-lowering agent; and at least one absorption enhancer effective to promote bioavailability of the active agent. The product is adapted for use in a method for enhancing the bioavailability of a therapeutic aromatic-cationic peptide delivered orally.
    Type: Application
    Filed: June 13, 2012
    Publication date: April 30, 2015
    Applicant: Stealth Peptides International, Inc.
    Inventor: D. Travis Wilson
  • Publication number: 20150119340
    Abstract: A fusion peptide including a hydrophobic peptide and a basic peptide, a pharmaceutical composition including the fusion peptide, a cell membrane penetrating conjugate including the fusion peptide and a substance of interest, and a method for intracellular delivery of a substance of interest using the fusion peptide.
    Type: Application
    Filed: October 29, 2014
    Publication date: April 30, 2015
    Inventors: Jung Min Kim, Kyoung Hu Lee, Jae Il Lee, Jungmin Lee
  • Publication number: 20150119328
    Abstract: Described herein are peptides, compositions, and related methods for treating upper gastrointestinal disorders and conditions (e.g., dyspepsia, gastroparesis, post-operative gastric ileus, a functional esophageal disorder, a functional gastroduodenal disorder, gastroesophageal reflux disease (GERD), or a duodenal or stomach ulcer) as well as other conditions and disorders that are described herein.
    Type: Application
    Filed: January 5, 2015
    Publication date: April 30, 2015
    Inventors: Mark G. Currie, Daniel P. Zimmer, Angelika Fretzen, Marco Kessler, Brian Cali
  • Patent number: 9018173
    Abstract: N-type voltage-gated calcium channels (CaV2.2) are critical mediators of neurotransmitter release and are thought to be involved with transmission of nociception. The use of conventional CaV2.2 blockers in pain therapeutics is limited by side effects. Reported herein is a means to suppress both inflammatory and neuropathic pain without directly blocking CaV2.2, but rather by inhibiting the binding of the axonal collapsin response mediator protein 2 (CRMP-2), a protein known to enhance CaV2.2 function. A 15 amino acid peptide of CRMP-2 fused to the protein transduction domain of the HIV tat protein (TAT CBD3) reduced meningeal blood flow induced by activation of the trigeminovascular system, prevented inflammation-induced tactile hypernociception induced by intraplantar formalin and nocifensive behavior following corneal capsaicin application, and reversed neuropathic hypernociception produced by the antiretroviral drug 2?,3?-dideoxycytidine. Preventing CRMP-2—mediated enhancement of CaV2.
    Type: Grant
    Filed: June 10, 2011
    Date of Patent: April 28, 2015
    Assignee: Indiana University Research and Technology Corp.
    Inventor: Rajesh Khanna
  • Publication number: 20150110797
    Abstract: Isolated peptides from the protein EMMPRIN (CD147/Basigin) and antibodies directed against antigenic determinants within the peptides. Pharmaceutical compositions including the peptides and antibodies and methods of their production and use in vaccination, immunotherapy and diagnosis of proliferative, hyperpermeability, inflammatory, and angiogenesis-related diseases and disorders.
    Type: Application
    Filed: September 30, 2014
    Publication date: April 23, 2015
    Inventors: Michal A. Rahat, Nitza Lahat, Miriam Walter, Haim Bitterman
  • Publication number: 20150111835
    Abstract: The present invention relates to a peptide, or a salt thereof, comprising or consisting of the amino acid sequence IHMVYSKRSGKPRGYAFIEY, comprising one or more post-translational modifications.
    Type: Application
    Filed: December 5, 2014
    Publication date: April 23, 2015
    Applicants: IMMUPHARMA FRANCE SA, CENTRE NATIONAL DE LA RECHERECHE SCIENTIFIQUE
    Inventors: Sylviane Muller, Jean-Paul Briand, Robert H. Zimmer
  • Patent number: 9012603
    Abstract: The invention relates to peptides which bind to human FcRn and inhibit binding of the Fc portion of an IgG to an FcRn, thereby modulating serum IgG levels. The disclosed compositions and methods may be used for example, in treating autoimmune diseases and inflammatory disorders. The invention also relates to methods of using and methods of making the peptides of the invention.
    Type: Grant
    Filed: December 18, 2009
    Date of Patent: April 21, 2015
    Assignee: Biogen Idec Hemophilia Inc.
    Inventors: Adam R. Mezo, Kevin A. McDonnell, Cristina A. Tan Hehir, Alfredo Castro
  • Publication number: 20150105334
    Abstract: The invention provides specific peptides derived from the cytotoxicity receptor NKp44 useful for preventing and treating serious diseases including in particular cancer. The invention further relates to compositions comprising a fragment of the extracellular region of NKp44 for preventing or treating cancer.
    Type: Application
    Filed: September 22, 2014
    Publication date: April 16, 2015
    Inventor: Angel PORGADOR
  • Publication number: 20150105327
    Abstract: This disclosure provides methods and compositions to inhibit or suppress tumor growth or to treat cancer by inhibiting VprBP kinase activity. Also provided are methods of determining the effectiveness of the methods and compositions to inhibit or suppress tumor growth or to treat cancer by inhibiting VprBP kinase activity, methods for detecting a cancer, and methods for screening potential agents that inhibit VprBP kinase activity.
    Type: Application
    Filed: October 14, 2014
    Publication date: April 16, 2015
    Inventors: Woojin An, Nouri Neamati, Kyunghwan Kim
  • Publication number: 20150105336
    Abstract: Provided is a mucosa-elevating agent containing 0.1% to 1.0% of a peptide, wherein the peptide is an amphipathic protein having 8 to 200 amino acid residues in which hydrophilic amino acids and hydrophobic amino acids are alternately bonded, and is a self-assembling peptide that exhibits a ? structure in an aqueous solution at physiological pH and/or in the presence of cations.
    Type: Application
    Filed: March 8, 2013
    Publication date: April 16, 2015
    Inventors: Kentaro Takamura, Satoru Kobayashi, Noriaki Matsuda
  • Publication number: 20150105335
    Abstract: The present invention provides, among other things, novel peptides and compositions for treating disease.
    Type: Application
    Filed: October 3, 2014
    Publication date: April 16, 2015
    Inventor: Richard Franklin